脳腫瘍治療薬の世界市場レポート 2025年

脳腫瘍治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.6％で、52億7,000万米ドルに成長します。予測期間の成長は、がん罹患率の増加、ヘルスケア支出の増加、高齢者人口の増加、強力な医薬品パイプライン、生物製剤医薬品開発を促進するためのFDA規制の改正などに起因すると考えられます。予測期間における主な動向としては、脳腫瘍治療のための薬剤の組み合わせへの投資、有効性を高めるための第0相臨床試験の利用、薬剤の有効性を高めるドラッグデリバリー技術の利用、細胞・遺伝子治療の拡大への注力、戦略的M&Aの実施などが挙げられます。

脳腫瘍治療薬市場の拡大に拍車をかけている主な触媒は、神経疾患の世界の有病率の上昇です。これらの疾患は、平均寿命の延長、感染症への曝露の増加、座りっぱなしのライフスタイルなどの要因により、ますます蔓延しています。例えば、全米脳腫瘍協会の報告によると、米国では現在約70万人が原発性脳腫瘍に罹患しており、さらに86,000人が診断を受けると予想されています。このような脳腫瘍を含む神経疾患の患者数の増加は、治療に使用される薬剤の需要増に直接的に寄与しており、脳腫瘍治療薬市場の成長を促進しています。

化学療法を受ける患者数の急増は、脳腫瘍治療薬の継続的な拡大を後押しする構えです。化学療法は、がん細胞のような急速に分裂する細胞を標的とし、根絶するために強力な薬剤を使用する重要な医療アプローチであり、脳腫瘍の治療の要となっています。効果的な化学療法薬の開発と入手のしやすさは、治療レジメン全体の成功に大きく影響します。化学療法の有効性は患者の生存率やQOLに大きな影響を与え、市場情勢に大きな影響を与えています。例えば、2023年7月の米国疾病予防管理センター（Centers for Disease Control and Prevention）のデータによると、米国では年間100万人以上のがん患者が化学療法や放射線療法を受けています。その結果、化学療法を選択する患者数の増加は、脳腫瘍治療薬市場の成長軌道を推進する極めて重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界脳腫瘍治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の脳腫瘍治療薬市場：成長率分析
• 世界の脳腫瘍治療薬市場の実績：規模と成長, 2019-2024
• 世界の脳腫瘍治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界脳腫瘍治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の脳腫瘍治療薬市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• テモゾロミド
• ベバシズマブ
• その他の薬物
• 世界の脳腫瘍治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局またはドラッグストア
• その他のエンドユーザー
• 世界の脳腫瘍治療薬市場、テモゾロミドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口製剤
• 注射剤
• 世界の脳腫瘍治療薬市場、ベバシズマブの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体療法
• 化学療法との併用療法
• 世界の脳腫瘍治療薬市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• カルムスチン
• ロムスチン
• エトポシド
• イリノテカン
• ノバントロン（ミトキサントロン）

第7章 地域別・国別分析

• 世界の脳腫瘍治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の脳腫瘍治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 脳腫瘍治療薬市場：競合情勢
• 脳腫瘍治療薬市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• CordenPharma
• Eisai Co., Ltd.
• Emcure Pharmaceuticals Limited
• Y-mAbs Therapeutics
• Roche India
• Novartis Oncology
• Arlak Biotech
• Healthkind Labs Pvt. Ltd.
• SwisscheM Healthcare Pvt.Ltd
• Apikos Pharma
• Kolaz Biotech
• CStone Pharma
• CARsgen Therapeutics
• JW Therapeutics
• BeiGene

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 脳腫瘍治療薬市場2029：新たな機会を提供する国
• 脳腫瘍治療薬市場2029：新たな機会を提供するセグメント
• 脳腫瘍治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Brain tumor drugs are medications utilized in the treatment of brain tumors, employing a range of approaches including chemotherapy, hormone therapies, anticonvulsants, and painkillers. While certain prescription drugs aim to manage symptoms during tumor treatment, chemotherapy specifically targets the reduction or destruction of brain tumors.

Key drugs in the realm of brain tumor treatment include temozolomide, carmustine, cisplatin, bevacizumab, gefitinib, and erlotinib. Temozolomide, for instance, is designed to treat specific types of brain cancer such as glioblastomamultiforme and anaplastic astrocytoma. These drugs fall under the category of antineoplastics, focusing on combating cancer. Various types of brain tumors, such as medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal (PNET), and others such as glioma, acoustic neuroma, and meningioma, are addressed using these drugs. The sectors benefiting from these treatments include hospital pharmacies, clinics, and other healthcare facilities.

The brain tumor drugs market research report is one of a series of new reports from The Business Research Company that provides brain tumor drugs market statistics, including brain tumor drugs industry global market size, regional shares, competitors with a brain tumor drugs market share, detailed brain tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the brain tumor drugs industry. This brain tumor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The brain tumor drugs market size has grown strongly in recent years. It will grow from $3.81 billion in 2024 to $4.09 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the increasing prevalence of neurological disorders, increased healthcare expenditure, increased number of approvals for oncology (cancer) drugs, increase in pharmaceutical R&D expenditure, and advances in cancer drug discovery.

The brain tumor drugs market size is expected to see strong growth in the next few years. It will grow to $5.27 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to an increase in cancer incidence rate, rise in healthcare expenditure, increasing geriatric population, strong pipeline of drugs, and revised FDA regulations to facilitate biologics drug development. Major trends in the forecast period include investing in a combination of drugs for brain tumor treatment, adapting the use of phase zero clinical trials to improve efficacy, use of technology for drug delivery that improves the efficacy of the drug, focusing on the expansion of cell and gene therapy, and carrying out strategic mergers and acquisitions.

The primary catalyst fueling the expansion of the Brain Tumor drugs market is the escalating prevalence of Neurological Disorders on a global scale. These disorders have become increasingly prevalent due to factors such as longer life expectancy, heightened exposure to infections, and sedentary lifestyles. For instance, as reported by the National Brain Tumor Society, approximately 700,000 individuals in the United States are currently affected by primary brain tumors, with an additional 86,000 expected to receive diagnoses. This growing population of individuals with neurological disorders, including brain tumors, is directly contributing to the increased demand for drugs utilized in their treatment, thereby fostering the growth of the brain tumor drugs market.

The surge in the number of patients undergoing chemotherapy is poised to drive the continued expansion of brain tumor drugs. Chemotherapy, a vital medical approach employing potent drugs to target and eradicate rapidly dividing cells such as cancer cells, remains a cornerstone treatment for brain tumors. The development and accessibility of effective chemotherapy drugs significantly influence the overall success of treatment regimens. The efficacy of chemotherapy profoundly impacts patient survival rates and enhances their quality of life, exerting a substantial influence on the market landscape. For instance, based on data from the Centers for Disease Control and Prevention in July 2023, over 1 million cancer patients in the United States undergo chemotherapy or radiation therapy annually. Consequently, the escalating number of patients opting for chemotherapy serves as a pivotal driver propelling the growth trajectory of the brain tumor drugs market.

Companies within the brain tumor drugs market are increasingly turning towards nanotechnology for treatment methodologies. Nanoparticles are being utilized as carriers for drugs, delivering them directly to cancer cells or into the tumor, yielding advantages such as reduced drug dosage, enhanced shelf life, and minimized toxicity. Some nanodrugs have proven effective in surmounting the blood-brain barrier, a historically significant challenge in treating brain tumors. Notably, nanoparticles such as Liposomes have facilitated targeted drug delivery to the core of cancer cells. Moreover, when coated with transferrin, these particles can breach the blood-brain barrier. Esteemed industry players such as GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are actively embracing this technology to advance medication and treatment techniques.

Key industry entities within the brain tumor drugs market are heavily invested in the development and approval of novel drugs, aiming to gain a competitive advantage. Drug approvals represent the regulatory process by which government health agencies authorize the marketing, sale, and prescription of new medications for specific medical conditions. For example, in June 2022, the United States Food and Drug Administration granted accelerated approval for a novel treatment combination incorporating the oral drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for advanced brain tumors exhibiting the BRAF V600E mutation. This approval extends to both adult and pediatric patients with high- and low-grade gliomas that have progressed post-prior treatments. Encouraging results from clinical trials revealed significant tumor reduction among patients receiving the combination therapy. Notably, positive responses were observed in 33% of high-grade glioma patients, 50% of low-grade glioma patients, and 25% of pediatric glioma patients. The BRAF V600E mutation is prevalent across various glioma types, including low-grade gliomas, pleomorphic xanthoastrocytomas (PXA), gangliogliomas, and pilocytic astrocytomas.

In September 2024, Stryker Corporation, a U.S.-based medical technology company focused on providing products and services to enhance healthcare outcomes, acquired NICO Corporation for an undisclosed amount. This acquisition aims to strengthen Stryker Corporation's minimally invasive neurosurgical solutions, especially for brain tumor removal and the treatment of intracerebral hemorrhage, thereby improving patient outcomes and fostering growth in its neurotechnology portfolio. NICO Corporation is a U.S.-based medical device company that specializes in developing minimally invasive neurosurgical technologies, particularly for the removal of brain tumors.

Major companies operating in the brain tumor drugs market include F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co., Ltd., Emcure Pharmaceuticals Limited, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Astellas Pharma Inc, Otsuka Pharmaceutical Co., Ltd, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratorios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.

North America was the largest region in the brain tumor drugs market in 2024. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The brain tumor drugs market consists of sales Afinitor (Everolimus), Afinitor Disperz (Everolimus), Belzutifan, and Bevacizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Brain Tumor Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on brain tumor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for brain tumor drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The brain tumor drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Temozolomide, Bevacizumab, Other Drugs
• 2) By End User: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other End-Users
• Subsegments:
• 1) By Temozolomide: Oral Formulation; Injectable Formulation
• 2) By Bevacizumab: Monoclonal Antibody Therapy; Combination Therapy With Chemotherapy
• 3) By Other Drugs: Carmustine; Lomustine; Etoposide; Irinotecan; Novantrone (Mitoxantrone)
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Novartis AG; Amgen Inc.; Pfizer Inc.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Brain Tumor Drugs Market Characteristics

3. Brain Tumor Drugs Market Trends And Strategies

4. Brain Tumor Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Brain Tumor Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Brain Tumor Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Brain Tumor Drugs Market Growth Rate Analysis
• 5.4. Global Brain Tumor Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Brain Tumor Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Brain Tumor Drugs Total Addressable Market (TAM)

6. Brain Tumor Drugs Market Segmentation

• 6.1. Global Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Temozolomide
• Bevacizumab
• Other Drugs
• 6.2. Global Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies Or Drug Stores
• Other End-Users
• 6.3. Global Brain Tumor Drugs Market, Sub-Segmentation Of Temozolomide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Formulation
• Injectable Formulation
• 6.4. Global Brain Tumor Drugs Market, Sub-Segmentation Of Bevacizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibody Therapy
• Combination Therapy With Chemotherapy
• 6.5. Global Brain Tumor Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Carmustine
• Lomustine
• Etoposide
• Irinotecan
• Novantrone (Mitoxantrone)

7. Brain Tumor Drugs Market Regional And Country Analysis

• 7.1. Global Brain Tumor Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Brain Tumor Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Brain Tumor Drugs Market

• 8.1. Asia-Pacific Brain Tumor Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Brain Tumor Drugs Market

• 9.1. China Brain Tumor Drugs Market Overview
• 9.2. China Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Brain Tumor Drugs Market

• 10.1. India Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Brain Tumor Drugs Market

• 11.1. Japan Brain Tumor Drugs Market Overview
• 11.2. Japan Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Brain Tumor Drugs Market

• 12.1. Australia Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Brain Tumor Drugs Market

• 13.1. Indonesia Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Brain Tumor Drugs Market

• 14.1. South Korea Brain Tumor Drugs Market Overview
• 14.2. South Korea Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Brain Tumor Drugs Market

• 15.1. Western Europe Brain Tumor Drugs Market Overview
• 15.2. Western Europe Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Brain Tumor Drugs Market

• 16.1. UK Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Brain Tumor Drugs Market

• 17.1. Germany Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Brain Tumor Drugs Market

• 18.1. France Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Brain Tumor Drugs Market

• 19.1. Italy Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Brain Tumor Drugs Market

• 20.1. Spain Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Brain Tumor Drugs Market

• 21.1. Eastern Europe Brain Tumor Drugs Market Overview
• 21.2. Eastern Europe Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Brain Tumor Drugs Market

• 22.1. Russia Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Brain Tumor Drugs Market

• 23.1. North America Brain Tumor Drugs Market Overview
• 23.2. North America Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Brain Tumor Drugs Market

• 24.1. USA Brain Tumor Drugs Market Overview
• 24.2. USA Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Brain Tumor Drugs Market

• 25.1. Canada Brain Tumor Drugs Market Overview
• 25.2. Canada Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Brain Tumor Drugs Market

• 26.1. South America Brain Tumor Drugs Market Overview
• 26.2. South America Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Brain Tumor Drugs Market

• 27.1. Brazil Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Brain Tumor Drugs Market

• 28.1. Middle East Brain Tumor Drugs Market Overview
• 28.2. Middle East Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Brain Tumor Drugs Market

• 29.1. Africa Brain Tumor Drugs Market Overview
• 29.2. Africa Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Brain Tumor Drugs Market Competitive Landscape And Company Profiles

• 30.1. Brain Tumor Drugs Market Competitive Landscape
• 30.2. Brain Tumor Drugs Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Brain Tumor Drugs Market Other Major And Innovative Companies

• 31.1. CordenPharma
• 31.2. Eisai Co., Ltd.
• 31.3. Emcure Pharmaceuticals Limited
• 31.4. Y-mAbs Therapeutics
• 31.5. Roche India
• 31.6. Novartis Oncology
• 31.7. Arlak Biotech
• 31.8. Healthkind Labs Pvt. Ltd.
• 31.9. SwisscheM Healthcare Pvt.Ltd
• 31.10. Apikos Pharma
• 31.11. Kolaz Biotech
• 31.12. CStone Pharma
• 31.13. CARsgen Therapeutics
• 31.14. JW Therapeutics
• 31.15. BeiGene

32. Global Brain Tumor Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Brain Tumor Drugs Market

34. Recent Developments In The Brain Tumor Drugs Market

35. Brain Tumor Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Brain Tumor Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Brain Tumor Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Brain Tumor Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer